Optic Neuritis

Categories: Rare diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Optic Neuritis

MalaCards integrated aliases for Optic Neuritis:

Name: Optic Neuritis 12 50 52 42 14 69


External Ids:

Disease Ontology 12 DOID:1210
ICD10 33 H46 H46.9
ICD9CM 35 377.3 377.30
MeSH 42 D009902
NCIt 47 C84950
UMLS 69 C0029134

Summaries for Optic Neuritis

NIH Rare Diseases : 50 optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain. the condition may cause sudden, reduced vision in the affected eye(s). while the cause of optic neuritis is unknown, it has been associated with autoimmune diseases, infections, multiple sclerosis, drug toxicity and deficiency of vitamin b-12. vision often returns to normal within 2-3 weeks without treatment. in some cases, corticosteroids are given to speed recovery. if known, the underlying cause should be treated. last updated: 1/11/2011

MalaCards based summary : Optic Neuritis is related to aseptic meningitis and ulcerative colitis, and has symptoms including eye manifestations An important gene associated with Optic Neuritis is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Toxoplasmosis and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include eye, brain and t cells, and related phenotypes are behavior/neurological and hematopoietic system

Disease Ontology : 12 An optic nerve disease that results_in inflammation located in optic nerve which may cause a complete or partial loss of vision.

Wikipedia : 72 Optic neuritis is a demyelinating inflammation of the optic nerve. It is also known as optic papillitis... more...

Related Diseases for Optic Neuritis

Diseases related to Optic Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 244)
id Related Disease Score Top Affiliating Genes
1 aseptic meningitis 30.3 HLA-DRB1 TNF
2 ulcerative colitis 30.0 AQP4 MBP TNF
3 toxoplasmosis 29.8 LTA TNF
4 neuromyelitis optica 11.6
5 transverse myelitis 11.3
6 optic papillitis 11.2
7 neuritis 11.0
8 optic nerve disease 10.9
9 cogan-reese syndrome 10.7 AQP4 MBP
10 biemond syndrome 10.7 HLA-DRB1 TNF
11 migraine with brainstem aura 10.7 HLA-DRB1 TNF
12 temporal arteritis 10.7 MBP MOG
13 pellagra like syndrome 10.7 HLA-DRB1 MOG
14 mosaic trisomy 1 10.6 HLA-DRB1 TNF
15 autoimmune retinopathy 10.6 HLA-DRB1 TNF
16 epstein-barr virus hepatitis 10.6 HLA-DRB1 TNF
17 anencephaly and spina bifida x-linked 10.6 HLA-DRB1 TNF
18 limb-body wall complex 10.6 HLA-DRB1 TNF
19 moved to 244450 10.6 HLA-DRB1 TNF
20 lens disease 10.6 AQP4 MBP
21 not otherwise specified 3-mga-uria type 10.6 HLA-DRB1 TNF
22 riboflavin transporter deficiency 10.6 HLA-DRB1 TNF
23 lymphocytic colitis 10.5 HLA-DRB1 TNF
24 central nervous system leiomyosarcoma 10.5 HLA-DRB1 TNF
25 ovarian surface papilloma 10.5 HLA-DRB1 MBP MOG
26 mixed cell adenoma 10.5 AQP4 MBP MOG
27 retinitis 10.5
28 diabetic peripheral angiopathy 10.5 AQP4 MOG
29 atypical lichen myxedematosus 10.5 CCR5 TNF
30 alopecia intellectual disability syndrome 2 10.5 MBP MOG PLP1
31 tricho onychic dysplasia 10.4 AQP4 MBP TNF
32 oropharyngeal cancer, childhood 10.4 CCR5 TNF
33 ovarian mucinous adenofibroma 10.4 MBP MOG TNF
34 submandibular gland disease 10.4 MAG TNF
35 eye carcinoma in situ 10.4 HLA-DRB1 MOG TNF
36 hepadnavirus infection 10.4 HLA-DRB1 TNF
37 pleomorphic carcinoma 10.4 AQP4 MOG MT-ND4
38 allergic contact dermatitis of eyelid 10.3 AQP4 MOG MT-ND4
39 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.3 CCR5 TNF
40 spondylocostal dysostosis 4 10.3 LTA TNF
41 type 1 papillary adenoma of the kidney 10.3 LTA TNF
42 spirillary rat-bite fever 10.3 LTA TNF
43 hypersplenism 10.3 AQP4 MAG MBP
44 idiopathic dilatation of the pulmonary artery 10.3 LTA TNF
45 indolent myeloma 10.3 MAG TNF
46 3-hydroxyacyl-coa dehydrogenase deficiency 10.3 MAG MBP
47 angioosteohypertrophic syndrome 10.3 MBP TNF
48 cauda equina syndrome 10.3 LTA TNF
49 newborn respiratory distress syndrome 10.2 AQP4 HLA-DRB1 MBP MOG
50 neuropathy 10.2

Comorbidity relations with Optic Neuritis via Phenotypic Disease Network (PDN):

Hypertension, Essential Temporal Arteritis

Graphical network of the top 20 diseases related to Optic Neuritis:

Diseases related to Optic Neuritis

Symptoms & Phenotypes for Optic Neuritis

UMLS symptoms related to Optic Neuritis:

eye manifestations

MGI Mouse Phenotypes related to Optic Neuritis:

id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 AQP4 CCR5 CNTF LTA MAG MBP
2 hematopoietic system MP:0005397 10.02 AQP4 CCR5 CNTF LTA MAG MBP
3 homeostasis/metabolism MP:0005376 9.96 AQP4 CCR5 CNTF LTA MAG MBP
4 immune system MP:0005387 9.9 MOG MPZ PLP1 SOD3 TNF AQP4
5 nervous system MP:0003631 9.65 MAG MBP MOG MPZ PLP1 TNF
6 vision/eye MP:0005391 9.17 AQP4 CCR5 LTA MBP MOG PLP1

Drugs & Therapeutics for Optic Neuritis

Drugs for Optic Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2 147245-92-9 3081884
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
Interferon beta-1a Approved, Investigational Phase 4,Phase 3 145258-61-3 6438354
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
10 Adrenocorticotropic Hormone Phase 4,Early Phase 1
11 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
14 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
15 beta-endorphin Phase 4,Early Phase 1
16 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
17 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
18 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Melanocyte-Stimulating Hormones Phase 4,Early Phase 1
22 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
23 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
24 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
27 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
28 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1
29 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Analgesics Phase 4
34 Topoisomerase Inhibitors Phase 4
35 Antimetabolites Phase 4,Phase 3,Phase 2
36 Vitamin B Complex Phase 4,Phase 1
37 Anti-Infective Agents Phase 4,Phase 2,Phase 3
38 Antiviral Agents Phase 4,Phase 2,Phase 3
39 Interferon-beta Phase 4,Phase 2,Phase 3
40 interferons Phase 4,Phase 2,Phase 3
41 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3
42 Dermatologic Agents Phase 4,Phase 2
43 Anti-Bacterial Agents Phase 4,Phase 2
44 Antibiotics, Antitubercular Phase 4
45 Folate Nutraceutical Phase 4,Phase 1
46 Vitamin B9 Nutraceutical Phase 4,Phase 1
Simvastatin Approved Phase 3 79902-63-9 54454
4-Aminopyridine Approved Phase 2, Phase 3 504-24-5 1727
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696

Interventional clinical trials:

(show top 50) (show all 91)

id Name Status NCT ID Phase Drugs
1 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV steroids with oral taper
2 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
3 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
4 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4 Prednisolone
5 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
6 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4 methylprednisolone;methylprednisolone;Placebo
7 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
8 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Enrolling by invitation NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
9 Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated NCT00854750 Phase 4 ACTHAR;ACTHAR;ACTHAR;ACTHAR
10 A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a Withdrawn NCT00771043 Phase 4 TYSABRI and AVONEX
11 Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
12 Simvastatin Treatment of Patients With Acute Optic Neuritis Unknown status NCT00261326 Phase 3 simvastatin;placebo
13 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
14 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
15 Optic Neuritis Recovery After Oral or IV Corticosteroids Completed NCT01524250 Phase 2, Phase 3 corticosteroids;corticosteroids
16 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon) Completed NCT00856635 Phase 3 Glatiramer Acetate;placebo
17 Ampyra for Optic Neuritis in MS Completed NCT01337986 Phase 2, Phase 3 Dalfampridine/Placebo;Placebo/Dalfampridine
18 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3 Immunoglobulin
19 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
20 Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study) Recruiting NCT02376881 Phase 3 Erythropoietin
21 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Recruiting NCT02028884 Phase 3 SA237;Placebo
22 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02200770 Phase 2, Phase 3
23 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Active, not recruiting NCT01962571 Phase 3 Erythropoietin alfa;Placebo
24 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3 MD1003 100mg capsule
25 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Active, not recruiting NCT01892345 Phase 3 Eculizumab
26 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 SA237;Placebo
27 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Enrolling by invitation NCT02003144 Phase 3
28 MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) Terminated NCT01647880 Phase 2, Phase 3 Verum arm receiving Gilenya®;Active Comparator receiving Extavia®
29 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
30 Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis Withdrawn NCT01337427 Phase 3 BIIB017
31 Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography Unknown status NCT01465893 Phase 2 Vitamin D;Vitamin D withheld
32 Amiloride Clinical Trial In Optic Neuritis Unknown status NCT01802489 Phase 2 Amiloride;Placebo
33 Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve Unknown status NCT01879527 Phase 2 Amiloride hydrochlorothiazide;Sugar pill
34 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
35 AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
36 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Unknown status NCT02249676 Phase 2
37 BIIB033 In Acute Optic Neuritis (AON) Completed NCT01721161 Phase 2 Placebo
38 Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis Completed NCT00355095 Phase 2 Erythropoietin
39 Neuroprotection With Phenytoin in Optic Neuritis Completed NCT01451593 Phase 2 Phenytoin;Placebo
40 Visual Reconstitution Therapy After Optic Neuritis Completed NCT01274702 Phase 2
41 Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) Completed NCT00395200 Phase 1, Phase 2
42 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2 cetirizine
43 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
44 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
45 Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis Completed NCT00772525 Phase 2 Nerispirdine;Placebo
46 Gypenosides Treatment for Optic Neuritis Recruiting NCT02976766 Phase 2 Gypenosides;Placebo
47 Effect of Phenytoin on the Ganglion Cell Inner Plexiform Layer and Visual Field in Patients With an Acute Optic Neuritis Recruiting NCT02939937 Phase 2 Phenytoin;placebo
48 Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) Recruiting NCT02521311 Phase 2 Clemastine;Placebo
49 Hematopoietic Stem Cell Transplant in Devic's Disease Recruiting NCT00787722 Phase 1, Phase 2
50 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Active, not recruiting NCT03062579 Phase 1, Phase 2 Tocilizumab

Search NIH Clinical Center for Optic Neuritis

Cochrane evidence based reviews: optic neuritis

Genetic Tests for Optic Neuritis

Anatomical Context for Optic Neuritis

MalaCards organs/tissues related to Optic Neuritis:

Eye, Brain, T Cells, Testes, Bone, Pituitary, Breast

Publications for Optic Neuritis

Articles related to Optic Neuritis:

(show top 50) (show all 758)
id Title Authors Year
Transorbital Sonography and Visual Outcome for the Diagnosis and Monitoring of Optic Neuritis. ( 27862614 )
Pediatric Optic Neuritis. ( 28941527 )
Cortical blindness and not optic neuritis as a cause of vision loss in a SjAPgren's syndrome (SS) patient with the neuromyelitis optica spectrum disorder (NMOSD): Challenges of ascribing demyelinating syndromes to SS: a case report. ( 28834867 )
Optic neuritis in a patient with celiac disease. ( 28803640 )
Vascular hypoperfusion in acute optic neuritis is a potentially new neurovascular model for demyelinating diseases. ( 28926646 )
Pediatric Optic Neuritis: What Is New. ( 28806345 )
Time is vision in recurrent optic neuritis. ( 28823952 )
The Renin-Angiotensin System Regulates Neurodegeneration in a Mouse Model of Optic Neuritis. ( 28919108 )
Concurrent intramedullary spinal cord and multiple intracranial tuberculomas with tuberculous optic neuritis: A rare case report. ( 28941861 )
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses. ( 28903961 )
Neuroprotection and visual function after optic neuritis. ( 27941524 )
Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. ( 28914353 )
Long-term structural retinal changes in patients with optic neuritis related to multiple sclerosis. ( 28860702 )
Retinal segmented layers with strong aquaporin-4 expression suffered more injuries in neuromyelitis optica spectrum disorders compared with optic neuritis with aquaporin-4 antibody seronegativity detected by optical coherence tomography. ( 28057643 )
Diagnostic accuracy of optical coherence tomography inter-eye percentage difference for optic neuritis in multiple sclerosis. ( 28887838 )
Acute Zonal Occult Outer Retinopathy Associated With Retrobulbar Optic Neuritis. ( 28252457 )
Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis. ( 28879451 )
Bevacizumab for Radiation Induced Optic Neuritis Among Aggressive Residual/Recurrent Suprasellar Tumors: More Than a Mere Antineoplastic Effect. ( 28754639 )
Should Oral Corticosteroids Be Used to Treat Demyelinating Optic Neuritis? ( 28857910 )
Prevalence and Incidence of Optic Neuritis in Patients with Different Types of Uveitis. ( 28895765 )
No evidence of association between optic neuritis and secondary LHON mtDNA mutations in patients with multiple sclerosis. ( 28802665 )
Optic neuritis: the eye as a window to the brain. ( 27906756 )
Isolated palatal weakness without optic neuritis as the presenting manifestation of multiple sclerosis and its diagnostic dilemma with acute disseminated encephalomyelitis in a young boy. ( 28469990 )
Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis. ( 28850630 )
Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study. ( 28125740 )
Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. ( 27844165 )
Postinfectious Anti-Myelin Oligodendrocyte Glycoprotein Antibody Positive Optic Neuritis and Myelitis. ( 28820014 )
20/40 or Better Visual Acuity After Optic Neuritis: Not as Good as We Once Thought? ( 27472185 )
Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis. ( 27919490 )
High sensitivity of diffusion tensor imaging in discriminating idiopathic demyelinating optic neuritis. ( 27500122 )
Serum sPECAM-1 and sVCAM-1 levels are associated with conversion to multiple sclerosis in patients with optic neuritis. ( 27806869 )
Recurrent optic neuritis and neuromyelitis optica-IgG following first and second human papillomavirus vaccinations. ( 27046292 )
Retinal ganglion cell and axonal loss in optic neuritis: risk factors and visual functions. ( 27858936 )
Optic neuritis with secondary retinal venous stasis in a case of abdominal tuberculosis. ( 27843238 )
Case-centered Analysis of Optic Neuritis After Vaccines. ( 27069066 )
Retinal nerve fiber layer thickness by Stratus and Cirrus OCT in retrobulbar optic neuritis and nonarteritic ischemic optic neuropathy. ( 27312208 )
Acute optic neuritis with diffusion restriction on MRI. ( 27655875 )
Optic neuritis with TNF alpha antagonists. ( 27213191 )
Pseudo-subarachnoid hemorrhage and optic neuritis in an 18-year-old girl with sodium valproate overdose. ( 27904589 )
Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. ( 27035900 )
Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis. ( 27171375 )
Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. ( 27049558 )
Occurrence of Optic Neuritis and Cervical Cord Schwannoma with Charcot-Marie-Tooth Type 4B1 Disease. ( 27162595 )
Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice. ( 27122964 )
Optic Nerve Sheath Meningioma Masquerading as Optic Neuritis. ( 26904329 )
A case of multiple evanescent white dot syndrome misdiagnosed as optic neuritis: Differential diagnosis for the neurologist. ( 27114663 )
Optic neuritis as an initial presentation of primary SjAPgren syndrome: A case report and literature review. ( 27858858 )
Vitamin D status is negatively correlated with retinal nerve fiber layer thickness in relapsing-remitting MS patients without acute optic neuritis. ( 27301383 )
Optic neuritis associated to treatment with infliximab. ( 28017474 )

Variations for Optic Neuritis

Expression for Optic Neuritis

Search GEO for disease gene expression data for Optic Neuritis.

Pathways for Optic Neuritis

Pathways related to Optic Neuritis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
Show member pathways
2 11.65 AQP4 PLP1 TNF
3 11.49 HLA-DRB1 MAG MPZ
4 11.34 AQP4 MAG MBP TNF
5 10.8 HLA-DRB1 TNF
6 9.7 MAG MBP PLP1

GO Terms for Optic Neuritis

Cellular components related to Optic Neuritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.96 AQP4 CCR5 HLA-DRB1 LTA MAG MBP
2 external side of plasma membrane GO:0009897 9.46 AQP4 CCR5 HLA-DRB1 TNF
3 myelin sheath GO:0043209 8.92 MAG MBP MPZ PLP1
4 compact myelin GO:0043218 8.65 MAG

Biological processes related to Optic Neuritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.65 CCR5 HLA-DRB1 LTA MBP TNF
2 negative regulation of growth of symbiont in host GO:0044130 9.43 LTA TNF
3 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.4 MAG MPZ
4 central nervous system myelination GO:0022010 9.37 MAG PLP1
5 myelination GO:0042552 9.33 MBP MPZ PLP1
6 axon ensheathment GO:0008366 9.32 MBP PLP1
7 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 8.96 LTA TNF
8 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 8.62 LTA TNF

Molecular functions related to Optic Neuritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.16 LTA TNF
2 structural constituent of myelin sheath GO:0019911 8.96 MBP PLP1
3 virus receptor activity GO:0001618 8.8 CCR5 HLA-DRB1 MOG

Sources for Optic Neuritis

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....